Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.
Type:
Application
Filed:
October 22, 2021
Publication date:
November 30, 2023
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITE D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventors:
Maria del Carmen MARTINEZ, Pierre BIGOT, Luisa VERGORI
Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.
Type:
Application
Filed:
October 8, 2021
Publication date:
November 23, 2023
Applicants:
UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventors:
Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.
Type:
Grant
Filed:
November 21, 2016
Date of Patent:
November 21, 2023
Assignees:
UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Dominique Bagnard, Aurore Fernandez, Laurent Jacob, Justine Fritz
Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
Type:
Application
Filed:
September 17, 2021
Publication date:
November 16, 2023
Applicants:
NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
Inventors:
Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
Type:
Grant
Filed:
March 9, 2021
Date of Patent:
November 14, 2023
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de Nantes
Inventors:
Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
Abstract: Devices and methods for reversibly stimulating neuronal cells in a subject. The devices include a module for generating ultrasounds at 4 MHz or more to stimulate neuronal cells expressing mechanosensitive channels with the ultrasounds. The methods include expressing mechanosensitive channels into neuronal cells and exposing the cells to ultrasounds at 4 MHz or more. Also, the use of the methods or devices for visual restoration in a subject.
Type:
Application
Filed:
September 9, 2021
Publication date:
October 19, 2023
Applicants:
SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventors:
Serge PICAUD, Sara CADONI, José-Alain SAHEL, Mickaël TANTER, Charlie DEMENE
Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
October 3, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)
Abstract: An in vitro assay for inducing extracellular trap (ET) formation, including contacting immune cells, in in vitro culture or within a biological sample, with immobilized human polyvalent immunoglobulins; and to uses thereof, in particular in an in vitro method for screening a drug for its ability to modulate ET formation, in an in vitro method for assessing the susceptibility of a subject to ET formation, in an in vitro method for predicting the response of a subject to a modulator of ET formation, and in in vitro method for monitoring the response of a subject to an immunomodulator.
Type:
Application
Filed:
February 10, 2023
Publication date:
September 14, 2023
Applicants:
Tridek-One Therapeutics, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris XIII, Université Paris Cité
Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
Type:
Grant
Filed:
October 12, 2020
Date of Patent:
September 12, 2023
Assignees:
Cytune Pharma, INSERM (Institut National de la Santé et de la Recherche Médicale)
Inventors:
Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
September 12, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES
Abstract: The use of recombinant AAV vectors expressing a molecule of interest in a method for treating diseases or conditions affecting the nervous system in a subject in need thereof, or in a method for increasing or inducing expression of the molecule of interest in the nervous system of a subject.
Type:
Application
Filed:
May 20, 2022
Publication date:
September 7, 2023
Applicants:
ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITE
Abstract: A non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject is provided. The method comprises the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. Also provided is a ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.
Type:
Grant
Filed:
March 15, 2017
Date of Patent:
August 29, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ CLAUDE BERNARD—LYON, CENTRE LEON BERARD, KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY)
Inventors:
Kim In-San, Philippe Bertolino, Ana Hennino
Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
August 15, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), NANTES UNIVERSITÈ, UNIVERSITE D'ANGERS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: Several new vector-promoter combinations to overcome the limitations associated with AAV-mediated cone transduction in the fovea are provided. The delivery modality relies on a cone-specific promoter and result in high-level transgene expression compatible with optogenetic vision restoration. Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vector comprising a VP1 capsid protein as set forth in SEQ ID NO: 11 and the polynucleotide of interest under the control of the pR1.7 promoter as set forth in SEQ ID NO: 12 are also provided.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
August 15, 2023
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
Abstract: An in vitro method of classifying a subject suspected to suffer from an acute event including the steps of: determining neopterin concentration in a biological sample obtained from the subject, comparing the concentration with a predetermined reference neopterin concentration, and assigning the subject to a risk group based on the comparison of the neopterin concentration with the predetermined reference neopterin concentration.
Type:
Application
Filed:
July 12, 2021
Publication date:
August 10, 2023
Applicants:
SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: Disclosed is a method utilizing (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or an analogue, pharmaceutically acceptable salt or solvate thereof for the treatment of a retinal disease, more specifically using mirabegron for the treatment of age-related macular degeneration. Also Disclosed is a pharmaceutical composition, a medicament and a kit for the treatment of age-related macular degeneration.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
August 8, 2023
Assignees:
SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
Type:
Grant
Filed:
March 13, 2020
Date of Patent:
July 18, 2023
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
Abstract: The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth regardation disorders, such as achondroplasia.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
July 11, 2023
Assignees:
Pfizer Inc., INSERM (Institut National de la Santé et de la Recherche Médicale), Université Côte d'Azur
Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Type:
Grant
Filed:
February 2, 2018
Date of Patent:
July 4, 2023
Assignees:
Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche
Médicale), Université Paris-Saclay
Inventors:
Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard